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ABSTRACT 
Objective: To assess the utility of number needed to treat (NNT) as a tool for cost effectiveness analysis. 
Methods: Two monoclonal antibodies (MAbs), used for induction therapy viz basiliximab and daclizumab in renal transplantation, were identified. 
Pivotal placebo controlled clinical trials, mentioned in the innovator package inserts, were compared and analyzed for acute graft rejection and graft 
survival at 12 mo. NNT viz-a-vis cost was calculated and compared.  
Results: Daclizumab was comparable to basiliximab for acute graft rejection (NNT 10 vs. 9) but better for graft survival (20 vs. 25) at 12 mo, when 
used along with triple drug regimen (cyclosporine, azathioprine and corticosteroid). However, considering the cost of regimen for these drugs, in 
terms of NNT, basiliximab was more cost effective (INR 12,52,044 vs. 28,70,400 for acute rejection and INR 34,77,900 vs. 57,40,800 for graft 
survival). On the other hand, when these MAbs were used along with dual drug regimen (cyclosporine and corticosteroid), daclizumab was more 
cost effective for graft survival at 12 mo. The higher cost of daclizumab regimen (INR 2,87,040 vs. 1,39,116 for basiliximab) was offset by its 
substantially lower NNT (20 vs. 58-75 for one extra graft survival at 12 mo).  
Conclusion: This study demonstrates the utility of NNT in ascertaining relative effectiveness of treatment modalities that would help to formulate 
appropriate healthcare policies. 
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INTRODUCTION 
World Trade Organization recognizes rational selection and use of 
medicines as one of the underpinning elements for access to 
medicines [1]. Reports show that nearly 50-80% Indian population 
is not able to access all the medicines that they need as 21.9% 
population is below poverty line and 60% of the total healthcare 
expenditure is out of pocket by patients themselves [2-4]. According 
to a World Bank study, large out of pocket medical costs may drive 
2.2% Indian population below the poverty line every year [2]. 
Clearly, cost of medicine is a big impediment in ensuring its access to 
the population. More so, new modalities of treatment, including 
newer drugs, are costlier as compared to their vintage counterparts, 
and, on top of that, may or may not be equally effective.  
Pharmacoeconomics is taken into account by drug regulators of 
Australia and some other countries before approving new drugs [5]. 
India approves drugs on the basis of a drug’s benefit-risk analysis and 
uses price capping of essential and certain other medicines. This 
becomes more significant in light of healthcare infrastructure in India 
and financial wherewithal of the population. Lack of such 
pharmacoeconomic consideration not only increases health care cost but 
the overall disease burden as well. For instance, the annual rate of renal 
transplantation in India is 3.25/million population/year, which is far low 
when compared to the prevalence of end-stage renal disease (ESRD) 
patients i.e., 150/million population/year. Data shows that>90% ESRD 
patients die within months of diagnosis as this therapy is either not 
affordable or not accessible [6]. Renal transplant requires long-term 
treatment with immunosuppressant’s to ensure graft survival and 
prevent graft rejection. Long-term immunosuppressive therapy is not 
only expensive but has its own adverse effects too [7]. Studies on clinical 
effectiveness and cost-effectiveness of such drugs might help clinicians to 
select a drug that is cost-effective and make a difference in the patient 
outcome by optimizing accessibility [6]. Similar studies have been 
undertaken for other therapeutic areas and have helped clinicians take 
the best course in a given situation [8]. However, the awareness 
regarding principles of pharmacoeconomics is scarce amongst medical 
professionals and needs to be augmented [9]. 
Number needed to treat (NNT) is a well-validated and commonly used 
measure of clinical significance of any intervention. It can be used to 
assess both advantages and disadvantages between two competing 
interventions. It is calculated as an inverse of the absolute risk reduction 
(ARR) due to a treatment modality and represents the number of 
patients that are required to be treated with a particular modality to 
prevent one additional target event (graft rejection AND graft survival in 
the context of this study). Lower NNT means that fewer patients need 
treatment with the drug for achieving an additional target event [10]. If 
the target event is a positive outcome, say cure, then the drug with lower 
NNT is more efficacious. NNT for clinical benefit and harm in respect of 
different treatment modalities, when juxtaposed with their cost of 
therapy, becomes a tool for cost-effectiveness analysis [11].  
In the present study, with post-transplant use of immunosuppressive 
drugs as a case in point, cost-effectiveness was evaluated. Two 
monoclonal antibodies (MAbs) viz basiliximab and daclizumab, 
recommended for use in patients undergoing renal transplantation to 
prevent graft rejection, were selected [12, 13]. These drugs are costly 
[14] and hence their accessibility is an issue in a resource limited 
setting. The rising incidence of chronic kidney disease and diabetic 
nephropathy makes the clinical condition pertinent. NNT was used as 
a tool to ascertain and compare the clinical effectiveness and cost-
effectiveness of basiliximab and daclizumab in combination 
immunosuppressive regimens for renal transplantation.  
MATERIALS AND METHODS 
Methods 
The study involved three steps i.e. ascertaining the efficacy of the 
drug from pivotal clinical trials’ data; calculating effectiveness of 
these drugs using NNT; and establishing cost of therapy based on 
prevalent market price of these drugs. 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                            Vol 12, Issue 6, 2020 
Mohan et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 6, 76-80 
77 
Drug information 
Innovator brands of basiliximab and daclizumab were identified. 
Package inserts of these innovator brands were analyzed for efficacy 
and safety data from pivotal clinical trials for licensing. Care was 
taken to compare only those clinical trials that had similar active 
comparator group (fig. 1). 
 
 
Fig. 1: Study summary, (Relative risk, RRR: relative risk reduction, ARR: absolute risk reduction; NNT: Number needed to treat; B-CAS: 
Basiliximab, cyclosporine, azathioprine and corticosteroid; D-CAS: Daclizumab, cyclosporine, azathioprine and corticosteroid; B-CS: 
Basiliximab, cyclosporine and corticosteroid; D-CS: Daclizumab, cyclosporine and corticosteroid) 
 
1. Pivotal clinical trials on Basiliximab:  
Three trials were reported in the package insert in adults receiving 
cadaveric-or living-donor renal transplantation.  
i) One study compared two 20 mg doses of basiliximab with 
placebo, both interventions administered in addition to standard 
immunosuppressive regimens containing cyclosporine, azathioprine 
and corticosteroid (triple drug regimen, acronym: B-CAS: n=172 in 
placebo group and n=168 in basiliximab group).  
ii) The other two studies compared two 20 mg doses of basiliximab 
with placebo, both drug administered in addition to immunosuppressive 
regimens containing cyclosporine and corticosteroids (dual drug 
regimen, acronym: B-CS1: n=185 in placebo group and n=190 in 
basiliximab group; acronym: B-CS2: n=173 in both groups).  
In all three studies, first dose of basiliximab or placebo was given 
within 2 h prior to transplantation surgery and the second dose was 
administered on Day 4 post transplantation [13]. 
2. Pivotal clinical trials on Daclizumab:  
Two trials compared a dose of 1 mg/kg/day of daclizumab with 
placebo in adult patients receiving cadaveric kidney transplant when 
both interventions (daclizumab and placebo) were administered in 
addition to standard immunosuppressive regimens containing 
either:  
i) Cyclosporine, azathioprine and corticosteroid (triple drug 
regimen, acronym: D-CAS: n=134 in placebo group and n=126 in 
daclizumab group) OR 
ii) Cyclosporine and corticosteroid (dual drug regimen, acronym: 
D-CS: n=134 in placebo group and n=141 in daclizumab group). 
In both these studies, dosing was initiated within 24 h pretransplant, 
with subsequent doses given every 14 d for a total of five doses [12]. 
Number needed to treat 
Number needed to treat was used to estimate relative effectiveness 
of the two study drugs. The calculation of number needed to treat 
included the following steps:  
• Identification of the target events as (i) graft rejection at 12 mo 
and (ii) graft survival at 12 mo  
• Extraction of incidence of these target events for 
basiliximab/daclizumab group and the corresponding placebo group 
from the selected studies  
• Calculation of Absolute Risk Reduction (ARR) as incidence of 
rejection or survival with placebo group minus the incidence of 
rejection with basiliximab/daclizumab group  
• Number needed to treat (NNT) was calculated as inverse of 
Absolute Risk Reduction (1/ARR) or 
i) Number needed to treat to prevent one graft rejection 
(NNTr)=1/(incidence of rejection with placebo group minus the 
incidence of rejection with drug group).  
ii) Number needed to treat to gain one additional graft survival 
(NNTs)=1/(incidence of graft survival with drug group minus the 
incidence of graft survival with placebo group). 
Cost of each target event with respect to cost of 
basiliximab/daclizumab 
Cost of individual drug therapy was calculated based on NNTs and 
total dose regime for daclizumab and basiliximab as follows:  
1. Cost of basiliximab/daclizumab required to prevent one additional 
graft rejection at 12 mo = NNTr X no of doses of basiliximab/daclizumab 
required per patient over 12 mo X cost of a single dose. 
2. Cost of basiliximab/daclizumab therapy required to gain one 
additional graft survival at 12 mo = NNTs X no of doses of 
basiliximab/daclizumab required per patient over 12 mo X cost of a 
single dose. 
The average adult dose of basiliximab was considered as 20 mg/day and 
that of daclizumab as 1 mg/kg/day, as recommended by FDA. Cost of a 
single dose was taken from a current commercial drug index in India and 
drug price listing websites for innovator brands [15, 16]. With the above 
data, cost comparison in terms of acute graft rejection and graft survival 
was carried out between basiliximab and daclizumab.  
RESULTS 
Analysis of graft rejection and survival 
In study 1 (B-CAS), the incidence of rejection in basiliximab arm and 
placebo arm meant that basiliximab led to an ARR of 11%. Besides, 
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basiliximab treatment was also able to provide 4 extra graft 
survivals for every 100 patients in drug treated group (92%-88%) 
during the same 12 mo period. 
In study 2 (D-CAS), patients in daclizumab group experienced 28% 
of biopsy proven acute rejection in 12 mo while patients in the 
placebo group experienced 38% of biopsy proven acute rejection at 
12 mo (table 1). Daclizumab group experienced 95% and placebo 
group experienced 90% graft survival at 12 mo. Addition of 
daclizumab to the standard triple drug regimen (CAS) was thus able 
to save additional 10 acute rejections (38-28%) and provide extra 5 
graft survival (95-90%) for every 100 patients at 12 mo. 
  
Table 1: Comparison of basiliximab and daclizumab with respect to the target events (acute rejection and graft survival at 12 mo) 
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Cost of 01 
additional graft 
survival (NNTs 
X drug cost) 
(INR) 
B-CAS 30 19 11 9 12,52,044 88 92 4 25 34,77,900 
D-CAS 38 28 10 10 28,70,400 90 95 5 20 57,40,800 
B-CS1 46 32 14 8 11,12,928 87 88 1 75 1,04,33,700 
B-CS2 49 35 14 8 11,12,928 93 95 2 58 80,68,728 
D-CS 49 28 21 5 14,35,200 83 88 5 20 57,40,800 
B-CAS: Basiliximab, cyclosporine, azathioprine and corticosteroid; D-CAS: Daclizumab, cyclosporine, azathioprine and corticosteroid; B-CS: Basiliximab, 
cyclosporine and corticosteroid; D-CS: Daclizumab, cyclosporine and corticosteroid; ARR: absolute risk reduction; Number needed to treat i.e. NNTr for 
acute rejection and NNTs for graft survival at 12 mo; Drug Cost: per patient per year cost of basiliximab = INR 1,39,116 and that of daclizumab = INR 
2,87,040; Incidence and ARR have been rounded off to the closest number and NNT has been rounded off to next higher number 
 
Two independent studies on basiliximab versus placebo on top of 
dual drug regimen showed large variation in acute rejection but 
relatively less variation in graft survival. In study 3 (B-CS1), and 
study 4 (B-CS2), the ARR for acute rejection was 14% at 12 mo. 
Though there was 1% increase in graft survival in study 3 and 2% 
increase in study 4 in basiliximab group compared to placebo, the 
percentage increase in basiliximab group varies, as 88% and 95% 
patients had graft survival in studies 3 and 4 respectively.  
In study 5 (D-CS), there was an increased difference in percentage of 
acute rejections between placebo and drug treated group. Adding 
daclizumab saved 21 (49%-28%) acute rejections for every 100 
patients at 12 mo. However, the percentage difference in graft 
survival was 5% at 12 mo. 
NNT for graft survival at 12 mo and NNT for graft rejection at 12 mo  
Study 1 (B-CAS): Basiliximab saved 1 extra acute rejection in every 9 
patients at 12 mo (NNTr at 12 mo = 9). NNTs for graft survival at 12 
mo was 25. 
Study 2 (D-CAS): Daclizumab had NNT of 10 for acute rejection 
(NNTr) at 12 mo of treatment. This implies that in order to save 1 
additional patient from graft rejection at 12 mo, we need to treat 10 
patients with daclizumab. Likewise, in order to have 1 extra graft 
survival at 12 mo, 20 patients need to be treated with daclizumab 
(NNTs at 12 mo = 20).  
In study 3 (B-CS1), for every 8 patients there was prevention of 1 
extra biopsy proven acute rejection with basiliximab at 12 mo as 
compared to placebo group (NNTr at 12 mo = 8). While in study 4 
(B-CS2), 1 in every 8 patients benefitted at 12 mo (NNTr at 12 mo = 
8). The NNTs was 75 and 58 for study 3 and 4 respectively (table 1). 
Study 5 (D-CS): Since NNTr at 12 mo was 5, 1 in every 5 patients is 
likely to be saved from acute rejections at 12 mo, if treated with 
daclizumab-based therapy. Also, daclizumab-based regimen was 
able to provide 1 extra graft survival for every 20 patients at 12 mo 
of treatment (NNTs at 12 mo = 20). 
Comparison of basiliximab and daclizumab in triple drug 
regimen 
The per patient cost of therapy for 12 mo in respect of basiliximab 
and daclizumab was estimated to be Rs 1,39,116 and Rs 2,87,040 
respectively, as per the dosing requirements and prevalent cost of 
innovator’s brand.  
The triple drug regimen in both the studies (B-CAS and D-CAS) 
consisted of cyclosporine, azathioprine and corticosteroid. In 
addition, basiliximab/daclizumab was added in the intervention 
group and placebo in the comparator group. In order to gain one 
extra graft survival at 12 mo, 25 patients need to be treated with 
basiliximab-based regimen and 20 patients with daclizumab-based 
regimen. Accordingly, INR 34,77,900 need to be spent on basiliximab 
(for 25 patients @ INR 1,39,116/patient/year) and INR 57,40,800 
need to be spent on daclizumab (for 20 patients @ INR 
2,87,040/patient/year) to gain one extra graft survival over and 
above the other direct and indirect costs. 
Similarly, in order to prevent one extra graft rejection at 12 mo, 9 
patients need to be treated with basiliximab thereby spending INR 
12,52,044/-while 10 patients need to be treated with daclizumab by 
spending INR 28,70,400/-over and above the other direct and 
indirect costs. 
Comparison of basiliximab and daclizumab in dual drug 
regimen  
Cyclosporine and corticosteroids were given in all the studies (B-CS1, 
B-CS2and D-CS). In addition, basiliximab or daclizumab was added in 
the intervention group vs placebo in the control group. In dual drug 
regimen, to gain one extra graft survival at 12 mo, 75 patients (B-
CS1) and 58 patients (B-CS2) needed to be treated with basiliximab 
and 20 patients need to be treated with daclizumab. Therefore, INR 
80,68,728/-to 1,04,33,700/-need to be spent on basiliximab and INR 
57,40,800/-on daclizumab to gain one extra graft survival at 12 mo. 
Similarly, in order to prevent one extra graft rejection at 12 mo, 8 
patients need to be treated with basiliximab thereby spending INR 
11,12,928/-but 5 patients need to be treated with daclizumab with 
an expenditure of INR 14,35,200/-over and above the comparator 
group and other drugs. 
DISCUSSION 
In India, nearly 80% of the tertiary care facilities providing 
transplant services are available only in the private sector which is 
out of the financial reach of an average Indian patient [17]. 
Moreover, health-care insurance coverage is available to<15% of the 
total Indian population [6]. This has reduced the deceased-donation 
rate to as low as 0.08 per million population per year [18]. 
Basiliximab and Daclizumab are IgG1 MAbs against interleukin-2 
receptor (CD25 antigen). Pivotal clinical trials show that induction 
therapy with basiliximab in two doses or daclizumab in five doses 
reduces the incidence of acute rejection and improves the chances of 
graft survival [12, 13]. However, pharmacoeconomic analysis of 
these clinically effective drugs is needed to select the more cost-
effective option of the two for poorer populations and especially in 
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countries like India. A concern often expressed by cost-effectiveness 
analysis researchers is that the results are not consistently 
implemented in practice settings because of the inability to 
conceptualize health economic measures and lack of relevance to 
clinical settings [11].  
If target events (such as graft rejection and graft survival) are 
presented along with economic end points (such as amount spent to 
prevent one acute rejection or to gain one graft survival), it is likely 
to improve understanding of health economic evidence by clinical 
decision-makers [11]. NNT is a useful absolute measure of treatment 
effect that expresses its magnitude in a clinically useful way. While 
the statistical significance of trial outcome denotes whether or not 
the result could have arisen by chance, NNT determines how 
frequently the outcome can be expected in a day-to-day clinical 
practice [11]. Therefore the concept of NNT is intuitively easy to 
comprehend and can also help in communicating this issue to 
patients. However, NNT can only be calculated for binary outcomes.  
In the present study, NNT was used as a tool to assess both clinical 
effectiveness and cost-effectiveness of basiliximab and daclizumab. 
Firstly the clinical effectiveness of study drugs was compared and 
then cost-effectiveness analysis was carried out. In triple drug 
regimen (cyclosporine, azathioprine and corticosteroid), daclizumab 
was comparable to basiliximab for acute graft rejection (NNTr 10 vs. 
9) at 12 mo but better for graft survival (NNTs 21 vs. 31) at 12 mo. 
However, considering the cost of regimen for these drugs in terms of 
NNT, basiliximab was found to have better cost effectiveness as 
compared to daclizumab.  
On the other hand, when these MAbs were used along with dual drug 
regimen, (cyclosporine and corticosteroid), daclizumab was more cost 
effective for graft survival at 12 mo. The higher cost of daclizumab was 
offset by its substantially lower NNT (20 vs. 58-75 for one extra graft 
survival at 12 mo). A US cost-effectiveness study comparing 
daclizumab to placebo suggested that daclizumab is cost-effective at 
10 y but not at 1 y, in terms of graft survival. Another study compared 
basiliximab to placebo and reported that basiliximab is cost-effective 
for graft survival at both 1-year and 10-year [19]. However, there are 
no head-on trials comparing basiliximab and daclizumab which makes 
selection of one drug difficult. 
There are some limitations in the present study. It includes only 
limited clinical trial data mentioned in the package insert wherein 
type of rejection is not mentioned; and only acute graft rejection and 
graft survival are considered in the study, setting aside other events 
that decide medical care. Cost of treating acute graft rejection has 
been taken as a constant, and therefore it has not been included in 
cost analysis. However, this cost varies from place to place. Head on 
comparative trial between basiliximab and daclizumab has not been 
carried out. However, care has been taken to include only those 
trials that had same comparator groups. We have reported only the 
point estimates for NNT and not its confidence interval(s) as it was 
imperative to use one single number so as to derive the cost of 
therapy for cost effectiveness analysis.  
Despite these limitations, our study demonstrates the utility of NNT 
in ascertaining relative cost effectiveness of treatment modalities. 
Such analysis needs to be undertaken on a large scale, taking 
maximum possible clinical data, so as to formulate appropriate 
policies that take due cognizance of economic aspects of therapeutic 
decision-making. Further, this ex ante evaluation requires field 
testing and ex post evaluation of incremental cost effectiveness ratio. 
CONCLUSION 
Use of NNT in cost-effectiveness analysis is a contemporary 
development. Besides, clinical relevance of a statistically significant 
result in the trial can be evaluated for likelihood of it getting encountered 
in day-to-day practice. This study demonstrates the utility of NNT in 
ascertaining relative cost effectiveness of treatment modalities that 
would help to formulate appropriate healthcare policies. 
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